Evidence map›Paper›PMID 28174232›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.

Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M Greer, L Austin Doyle, John J Wright, Judith E Karp, Michelle A Rudek

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Flavopiridol restores granulopoiesis in experimental models of severe congenital neutropenia.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  2. Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Carl LaCerteCenter for Translational Medicine, University of Maryland, Baltimore, Maryland.
Vijay IvaturiCenter for Translational Medicine, University of Maryland, Baltimore, Maryland. mrudek2@jhmi.edu vivaturi@rx.umaryland.edu.
Joga GobburuCenter for Translational Medicine, University of Maryland, Baltimore, Maryland.
Jacqueline M GreerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
L Austin DoyleInvestigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
John J WrightInvestigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Judith E KarpThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Michelle A RudekThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. mrudek2@jhmi.edu vivaturi@rx.umaryland.edu.
Sidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
The Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9M
PHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6M
Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
$4.1M
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCI NIH HHS U01 CA070095NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186716
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, PharmacologicalCytarabineDrug Administration ScheduleFemaleFlavonoidsHumansLeukemia, Myeloid, AcuteMaleMaximum Tolerated DoseMiddle AgedMitoxantronePiperidinesVidarabinealvocidibBiomarkers, PharmacologicalCytarabineFlavonoidsMitoxantronePiperidinesVidarabine

Identifiers

PMID28174232
PMCPMC5511568
OpenAlexW2586989097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.